Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin i

Journal of Medicinal Chemistry

Volumn 54, Issue 10, 2011, Pages 3506-3523

  Khupse, Rahul S ^b   Sarver, Jeffrey G ^a   Trendel, Jill A ^a   Bearss, Nicole R ^a   Reese, Michael D ^a   Wiese, Thomas E ^c   Boue, Stephen M ^d   Burow, Matthew E ^e   Cleveland, Thomas E ^d   Bhatnagar, Deepak ^d   Erhardt, Paul W ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF FINDLAY   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

^d SOUTHERN REGIONAL RESEARCH CENTER   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMIMETIC MATERIAL; ESTROGEN RECEPTOR; GLYCEOLLIN I; PHYTOALEXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BIOMIMETICS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, CHEMICAL; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; PTEROCARPANS; RECEPTORS, ESTROGEN; STEREOISOMERISM;

EID: 79957730707     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101619e     Document Type: Article

References (130)

1. Sporn, M. B.; Dunlop, N. M.; Newton, D. L.; Smith, J. M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed. Proc. 1976, 35, 1332-1338
2. Sporn, M. B. Approaches to prevention of epithelial cancer during the preneoplastic period Cancer Res. 1976, 36, 2699-2702
3. Sporn, M. B.; Newton, D. L. Chemoprevention of cancer and retinoids Fed. Proc. 1979, 38, 2528-2534
4. Weinstein, B. Cancer prevention: recent progress and future opportunities Cancer Res. 1991, 51, 5080s-5085s
5. Persky, V.; Van Horn, L. Epidemiology of soy and cancer: perspectives and directions J. Nutr. 1995, 125, 709s-712s
6. Herman, C.; Adlercreutz, T.; Goldin, B. R.; Gorbach, S. L.; Hockerstedt, K. A. V.; Watanabe, S.; Hamalainen, E. K.; Markkanen, M. H.; Makela, T. H. Soybean phytoestrogen intake and cancer risk J. Nutr. 1995, 125, 757s-770s
7. Baird, D. D.; Umbach, D. M.; Lansdell, L.; Hughes, C. L.; Setchell, K. D. R.; Weinberg, C. R.; Haney, A. F.; Wilcox, A. J.; McLachlan, J. A. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women J. Clin. Endocrinol. Metab. 1995, 80, 1685-1690
8. Jordan, V. C. Selective estrogen receptor modulation: a personal perspective Cancer Res. 2001, 61, 5683-5687 (Pubitemid 32769076)
9. Manson, M. M. Cancer prevention: the potential for diet to modulate cellular signaling Trends Mol. Med. 2003, 9, 11-18 (Pubitemid 36139250)
10. Surh, Y.-J. Cancer chemoprevention with dietary phytochemicals Nature Rev. Cancer 2003, 3, 768-780 (Pubitemid 37328815)
11. Girnun, G. D.; Howe, L. R.; Manne, S.; Mao, J. T.; Reid, M. E.; Szabo, E. International Conference on Frontiers in Cancer Prevention Research Cancer Prevention Res. 2008, 1, 146-149
12. Bode, A. M.; Dong, Z. Cancer prevention research-then and now Nature Rev. Cancer 2009, 9, 508-516
13. Ludwig, J. A.; Weinstein, J. N. Biomarkers in cancer staging, prognosis and treatment selection Nature Rev. Cancer 2005, 5, 845-856 (Pubitemid 41746029)
14. Fraser, G. A. M.; Meyer, R. M. Biomarkers and the design of clinical trials in cancer Biomarkers Med. 2007, 1, 387-397
15. The following definitions, as meant for use herein, have been adapted from a Health Canada Policy Paper which appeared on www.ana-jana.org (a) functional foods are items consumed as part of the usual diet that have been demonstrated to have physiological benefits or to reduce the risk of disease beyond basic nutritional factors, (b) nutraceuticals are items isolated or purified from foods generally taken in medicinal forms not associated with the usual diet, that have been demonstrated to have physiological benefits or to reduce the risk of disease, and (c) fortification is a process that alters the content of a dietary supplement's constituents such that there is an enhancement of the beneficial physiological effects or further reduction in the risk of disease. For a brief review of these terms and topic, see
16. Monge, A.; Cardozo, T.; Barreiro, E. J.; Huenchunir, P.; Pinzon, R.; Mora, G.; Nunez, A.; Chiriboga, X.; Caceres, A.; Rivera, G.; Bocanegra-Garcia, V.; Gupta, M.; Ferro, E. A.; Peralta, I.; Lock, O.; Flores, D.; Salazar, L.; Guzman, O. D.; Cerecetto, H.; Gonzalez, M. Functional foods, reflections on an expanding market. Chem. Int. 2008, Sept-Oct) 9-13.
17. Faghihi, J.; Jiang, X.; Vierling, R.; Goldman, S.; Sharfstein, S.; Sarver, J.; Erhardt, P. Reproducibility of the high-performance liquid chromatographic fingerprints obtained from two soybean cultivars and a selected progeny. J. Chromatogr., A 2001, 915, 61-74 (with subsequent erratum noted (Pubitemid 32289326)
18. 2003, 989, 317
19. The following definitions, as meant for use herein, have been adapted from analogies to the development of small molecule pharmaceutical agents wherein the attrition rates observed during drug development candidates derived from new mechanistic pathways thought to represent novel therapeutic targets, and likewise for their accompanying "drug wannabe" compounds, is so high that success in preclinical models is now regarded by many as being only a credentialization of such pathways and their associated compounds, rather than as a validation. Actual validation is then reserved for success observed in clinical studies. For discussions of this topic, see: Erhardt, P. W.; Proudfoot, J. R. Drug Discovery: Historical Perspective, Current Status, and Outlook. In Comprehensive Medicinal Chemistry II; Taylor, J. B.; Triggle, D. J.; Kennewell, P. D., Eds.; Elsevier, Ltd.: Oxford, U.K, 2007; pp 29-96.
20. Erhardt, P. W. Drug Discovery. In Pharmacology-Principles and Practice; Hacker, M.; Bachmann, K.; Messer, W., Eds.; Elsevier, Ltd.: Oxford, 2009; pp 475-560.
21. Corpet, D. E.; Pierre, F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men Eur. J. Cancer 2005, 41, 1911-1922 (Pubitemid 41557677)
22. Jankowski, J. A.; Hawk, E. T. A. Methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer Nature Clin. Pract. Gastroenterol. Hepatol. 2006, 3, 101-111
23. Potti, A.; Schilsky, R. L.; Nevins, J. R. Refocusing the war on cancer: the critical war of personalized treatment Sci. Transl. Med. 2010, 2, 1-3
24. Boue, S. M.; Cleveland, T. E.; Shih, B. Y.; Carter-Wientjes, C.; McLachlan, J. A.; Burow, M. E. Phytoalexin-enriched functional foods J. Agric. Food Chem. 2009, 57, 2614-2622
25. Jiménez-González, L.; Álvarez-Corral, M.; Muñoz-Dorado, M.; Rodríguez-García, I. Pterocarpans: interesting natural products with antifungal activity and other biological properties Phytochem. Rev. 2007, 7, 125-154
26. Al-Hazimi, H. M. G.; Alkhathlan, H. Z. Naturally occurring pterocarpanoids and related compounds J. King Saud Univ. 2000, 12, 93-122
27. Bailey, J. A.; Mansfield, J. W. In Phytoalexins; Wiley, Inc.: New York, 1982; pp 1-322.
28. Hammerschmidt, R. Phytoalexins: what have we learned after 60 years? Annu. Rev. Phytopathol. 1999, 37, 285-306 (Pubitemid 29523937)
29. Boue, S. M.; Carter, C. H.; Ehrlich, K. C; Cleveland, T. E. Induction of the soybean phytoalexins coumestrol and glyceollin by aspergillus J. Agric. Food Chem. 2000, 48, 2167-2172 (Pubitemid 30431206)
30. Cleveland, T. E.; Boue, S. M.; Burow, M. E.; McLachlan, J. A. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis. U.S. Patent Appl. US 2006246162, 2006; 16 pp.
31. Boue, S. M.; Shih, F. F.; Daigle, K. W.; Carter-Wientjes, C.; Shih, B. Y.; Cleveland, T. E. Effect of biotic elicitors on enrichment of antioxidant properties of induced isoflavones in soybean J. Food Sci. 2008, 73, 43-49
32. Majid, S.; Kikuno, N.; Nelles, J.; Noonan, E.; Tanaka, Y.; Kawamoto, K.; Hirata, H.; Li, L. C.; Zhao, H.; Okino, S. T.; Place, R. F.; Pookot, D.; Dahiya, R. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification Cancer Res. 2008, 68, 2736-2744 (Pubitemid 351556271)
33. Collins, B. M.; McLachlan, J. A.; Arnold, S. F. The estrogenic and anti-estrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast Steroids 1997, 62, 1-7
34. Collins-Burow, B. M.; Burrow, M. E.; Duong, B. N.; McLachlan, J. A. The estrogenic and anti-estrogenic activities of flavonoid phytochemicals through estrogen receptor binding dependent and independent mechanisms Nutr. Cancer 2000, 38, 229-244 (Pubitemid 32762024)
35. Nikov, G.; Hopkins, N.; Boue, S. M.; Alworth, W. Interactions of dietary estrogens with human estrogen receptors and the effect of estrogen receptor-estrogen response element complex formation Environ. Health Perspect. 2000, 108, 862-872
36. Burow, M. E.; Boue, S. M.; Collins-Burow, B. M.; Melnik, L. I.; Duong, B. N.; Carter-Wientjes, C. H.; Li, S.; Wiese, T. E.; Cleveland, T. E.; McLachlan, J. A. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor α and β J. Clin. Endocrinol. Metab. 2001, 86, 1750-1758 (Pubitemid 32377291)
37. Frigo, D. E.; Duong, B. N.; Melnik, L. I.; Schief, L.; Collins-Burow, B. M.; Pace, D. K.; McLachlan, J. A.; Burow, M. E. Flavonoid phytochemicals regulate multiple signal transduction pathways in endometrial and kidney stable cell lines J. Nutr. 2002, 132, 1848-1853 (Pubitemid 34742867)
38. Salvo, V.; Boue, S.; Fonseca, J.; Elliott, S.; Corbitt, C.; Collins-Burrow, B.; Curiel, T.; Shih, B.; Carter-Wientjes, C.; Wood, C.; Erhardt, P.; Beckman, B.; McLachlan, J.; Cleveland, T. E.; Burow, M. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis Clin. Cancer Res. 2006, 12, 7159-7164 (Pubitemid 44974517)
39. Erhardt, P. W.; Khupse, R. S.; Sarver, J. G.; Cleaveland, T. E.; Boue, S. M.; Wiese, T. E.; Burow, M. E.; McLachlan, J. A. Methods For Synthesizing Glycinols, Glyceollins I and Glyceollins II, Compositions Of Selected Intermediates, And Uses Directed Toward Therapeutic Applications. Patent Application submitted, 2008; pp 1-65.
40. Payton-Stewart, F.; Schoene, N. W.; Kim, Y.; Burow, M. E.; Cleveland, T. E.; Boue, S.; Wang, T. Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP Mol. Carcinog. 2009, 48, 862-871
41. Boue, S. M.; Wiese, T. E.; Nehls, S.; Burrow, M. E.; Elliott, S.; Carter-Wientjes, C. H.; Shih, B. Y.; McLachlan, J. A.; Cleveland, T. E. Evaluation of the estrogenic effects of legume extracts containing phytoestrogens J. Agric. Food Chem. 2003, 51, 2193-2199
42. Wood, C. E.; Clarkson, T. B.; Appt, S. E.; Franke, A. A.; Boue, S. M.; Burow, M. E.; Cline, J. M. Interactive effects of soybean glyceollins and estradiol in the breast Nutr. Cancer 2006, 56, 74-81 (Pubitemid 46173416)
43. Park, W.-C.; Jordan, V. C. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention Trends Mol. Med. 2002, 8, 82-88 (Pubitemid 34094444)
44. La Vecchia, C.; Gallus, S.; Fernandez, E. Hormone replacement therapy and colorectal cancer: an update J. Br. Menopause Soc. 2005, 11, 166-172 (Pubitemid 43103245)
45. Newcomb, P. A.; Zheng, Y.; Chia, V. M.; Morimoto, L. M.; Doria-Rose, V. P; Templeton, A.; Thibodeau, S. N.; Potter, J. D. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women Cancer Res. 2007, 67, 7534-7539 (Pubitemid 47206584)
46. Zimmerman, M. C.; Tilghman, S. L.; Boue, S. M.; Salvo, V. A.; Elliott, S.; Williams, K. Y.; Shripnikova, E. V.; Ashe, H.; Payton-Stewart, F.; Vanhoy-Rhodes, L.; Fonesca, J. P.; Corbitt, C.; Collins-Burow, B.; Howell, M. S.; Lacey, M.; Shih, B. Y.; Carter-Wientjes, C.; Segar, C.; Beckman, B.; Wiese, T. E.; McLachlan, J. A.; Cleveland, T. E.; Burow, M. E. Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy J. Pharmacol. Exp. Ther. 2010, 332, 35-45
47. Payton-Stewart, F.; Khupse, R. S.; Boue, S. M.; Elliott, S.; Zimmermann, M. C.; Skripnikova, E. V.; Ashe, H.; Tilghman, S. L.; Beckman, B. S.; Cleveland, T. E.; McLachlan, J. A.; Bhatnagar, D.; Wiese, T. E.; Erhardt, P.; Burow, M. E. Glyceollin I enantiomers distinctly regulate ER-mediated gene expression Steroids 2010, 75, 870-878
48. Boue, S. M.; Tilghman, S. L.; Elliott, S.; Zimmerman, M. C.; Williams, K. Y.; Payton-Stewart, F.; Miraflor, A. P.; Howell, M. S.; Shih, B. Y.; Carter-Wientjes, C.; Segar, C.; Beckman, B.; Wiese, T. E.; McLachlan, J. A.; Cleveland, T. E.; Burow, M. E. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max.) Endocrinology 2009, 150, 2446-2453
49. Nagy, P. I.; Erhardt, P. Ab initio study of hydrogen-bond formation between cyclic ethers and selected amino acid side-chains J. Phys. Chem. A 2006, 110, 13923-13932 (Pubitemid 46133412)
50. Nagy, P.; Erhardt, P. Ab initio study of hydrogen-bond formation between aliphatic and phenolic hydroxy groups and selected amino acid side-chains J. Phys. Chem. A 2008, 112, 4342-4350
51. Nagy, P.; Erhardt, P. Theoretical studies of salt-bridge formation by amino acid side-chains in low and medium polarity environments J. Phys. Chem. A 2010, 114, 16436-16442
52. Khupse, R. S.; Erhardt, P. W. Toward the total synthesis of racemic glyceollin I. 30th National Medicinal Chemistry Symposium, Seattle, WA, June 25-29, 2006, Abstract 87.
53. Khupse, R. S.; Erhardt, P. W. Toward the total synthesis of natural glyceollin I. 234th National ACS Meeting, Boston, MA, August 19-23, 2007, Abstract MEDI-182.
54. Khupse, R. S.; Erhardt, P. W. Total synthesis of xanthohumol J. Nat. Prod. 2007, 70, 1507-1509 (Pubitemid 47584599)
55. 1 J. Nat. Prod. 2008, 71, 275-277
56. Khupse, R. S.; Erhardt, P. W. Total syntheses of racemic, natural (-) and unnatural (+) glyceollin I Org. Lett. 2008, 10, 5007-5010
57. Luniwal, A.; Khupse, R.; Reese, M.; Fang, L.; Erhardt, P. Total synthesis of racemic and natural glycinol J. Nat. Prod. 2009, 72, 2072-2075
58. The Flavonoids, Advances in Research Since 1986; Harborne, J. B., Ed.; Chapman and Hall: London, UK, 1994; pp 1-178.
59. Cruickshank, I. A. M.; Perrin, D. R. Isolation of a phytoalexin from Pisum sativum Nature 1960, 187, 799-800
60. Mori, K.; Kisida, H. Syntheses of pterocarpans. II. Synthesis of both the enantiomers of pisatin Liebigs Ann. Chem. 1989, 35-39
61. van Aardt, T. G.; van Rensburg, H.; Ferreira, D. Synthesis of isoflavonoids. Enantiopure cis-and trans -6a-hydroxypterocarpans and a racemic trans -pterocarpan Tetrahedron 2001, 57, 7113-7126
62. Sims, J. J.; Keen, N. T.; Honwad, V. K. Hydroxyphaseollin, and induced antifungal compound from soybeans Phytochemistry 1972, 11, 827-828
63. Burden, R. S.; Bailey, J. A. Structure of the phytoalexin from soybean Phytochemistry 1975, 14, 1389-1390
64. Pelter, A.; Stainton, P. Mass spectra of oxygen heterocycles. I. 4-Hydroxy-3-phenylcoumarins isoflavonols J. Heterocycl. Chem 1965, 2, 256-261
65. Lyne, R. L.; Mulheirn, L. J.; Leworthy, D. P. New pterocarpinoid phytoalexins of soybean Chem. Commun. 1976, 497-498
66. Partridge, J. E.; Keen, N. T. Soybean phytoalexins: rates of synthesis are not regulated by activation of initial enzymes in flavonoid biosynthesis Phytopathology 1977, 67, 50-55
67. Jiménez-González, L.; Álvarez-Corral, M.; Muñoz-Dorado, M.; Rodríguez-García, I. A concise and diastereoselective total synthesis of cis-and trans -pterocarpans Chem. Commun. 2005, 2689-2691 (Pubitemid 40861690)
68. Engler, T. A.; LaTessa, K. O.; Iyengar, R.; Chai, W.; Agrios, K. Stereoselective syntheses of substituted pterocarpans with anti-HIV activity, and 5-aza-/5-thia-pterocarpan and 2-aryl-2,3-dihydrobenzofuran analogs Bioorg. Med. Chem. 1996, 4, 1755-1769 (Pubitemid 26361881)
69. da Silva, A. J. M.; Coelho, A. L.; Simas, A. B. C.; Moraes, R. A. M.; Pinheiro, D. A.; Fernandes, F. F.; Arruda, E. Z.; Costa, P. R.; Melo, P. A. Synthesis and pharmacological evaluation of prenylated and benzylated pterocarpans against snake venom Bioorg. Med. Chem. 2004, 14, 431-435 (Pubitemid 38045139)
70. Schoening, A.; Friedrichsen, W. The stereochemistry of pterocarpanoids. A theoretical study Z. Naturforsch., B: Chem. Sci. 1989, 44, 975-982
71. Pinard, E.; Gaudry, M.; Henot, F.; Thellend, A. Asymmetric total synthesis of (+)-pisatin, a phytoalexin from garden peas (Pisum sativum L.) Tetrahedron. Lett. 1998, 39, 2739-2742 (Pubitemid 28186665)
72. Doucet, H.; Fernandez, E.; Layzell, T. P.; Brown, J. M. The scope of catalytic asymmetric hydroboration/oxidation with rhodium complexes of 1,1′-(2-diarylphosphino-1-naphthyl)isoquinolines Eur. J. Chem. 1999, 5, 1320-1330
73. Tsukayama, M.; Fujimoto, K.; Horie, T.; Masumura, M.; Nakayama, M. Synthesis of licoisoflavone A and related compounds Bull. Chem. Soc. Jpn. 1985, 58, 136-141
74. Anzeveno, P. B. Rotenoid interconversion. Synthesis of deguelin from rotenone J. Org. Chem. 1979, 44, 2578-2580
75. Chen, F. C.; Chen, T. S.; Ueng, T. Synthesis of 2′-, 3′-, and 4′-fluoroflavone J. Chin. Chem. Soc. 1962, 9, 308-310
76. Suesse, M.; Johne, S.; Hesse, M. Synthesis and reactions of 2′-substituted isoflavones Helv. Chim. Acta 1992, 75, 457-470
77. Moriarty, R. M.; Khosrowshahi, J. S.; Prakash, O. Solvohyperiodination. A comparison with solvothallation Tetrahedron Lett. 1985, 26, 2961-2964
78. McKillop, A.; Swann, B. P.; Taylor, E. C. Thallium in organic synthesis. XXXIII. One-step synthesis of methyl arylacetates from acetophenones using thallium (III) nitrate (TTN) J. Am. Chem. Soc. 1973, 95, 3340-3343
79. McKillop, A.; Swann, B. P.; Ford, M. E.; Taylor, E. C. Thallium in organic synthesis. XXXVIII. Oxidation of chalcones, deoxybenzoins, and benzoins with thallium (III) nitrate (TTN) J. Am. Chem. Soc. 1973, 95, 3641-3645
80. Horie, T.; Yamada, T.; Kawamura, Y.; Tsukayama, M.; Kuramoto, M. Oxidation of 2′-hydroxyacetophenones with thallium (III) nitrate in methanol J. Org. Chem. 1992, 57, 1038-1042
81. Horie, T.; Kawamura, Y.; Sakai, C.; Akita, A.; Sasagawa, M.; Yamada, T. Oxidative rearrangement of 2′-hydroxychalcones having no substituent at the 3′- and 5′-positions with thallium (III) nitrate in methanol J. Chem. Soc., Perkin Trans. 1996, 1987-1992 (Pubitemid 126801328)
82. Taylor, E. C.; Robey, R. L.; Liu, K. T.; Favre, B.; Bozimo, H. T.; Conley, R. A.; Chiang, C. S.; McKillop, A.; Ford, M. E. Thallium in organic synthesis. 43. Novel oxidative rearrangements with thallium (III) nitrate (TTN) in trimethyl orthoformate (TMOF) J. Am. Chem. Soc. 1976, 98, 3037-3038
83. Kojima, A.; Takemoto, T.; Sodeoka, M.; Shibasaki, M. Catalytic asymmetric synthesis of halenaquinone and halenaquinol J. Org. Chem. 1996, 61, 4876-4877 (Pubitemid 26256849)
84. Major, A.; Nogradi, M.; Vermes, B.; Kajtar-Peredy, M. Synthesis of the natural isoflav-3-enes haginin A, B, and D Liebigs Ann. Chem. 1988, 6, 555-558
85. Kolb, H. C.; van Nieuwenhze, M. S.; Sharpless, K. B. Catalytic asymmetric dihydroxylation Chem. Rev. 1994, 94, 2483-2547 (Pubitemid 24987874)
86. Norrby, P. O.; Kolb, H. C.; Sharpless, K. B. Toward an understanding of the high enantioselectivity in the osmium-catalyzed asymmetric dihydroxylation. 2. A qualitative molecular mechanics approach J. Am. Chem. Soc. 1994, 116, 8470-8478 (Pubitemid 24981580)
87. Prasad, A. V. K.; Kapil, R. S.; Popli, S. P. Synthesis of (+)-isomedicarpin, (+)-homopterocarpin and tuberostan: a novel entry of hydrogenative cyclization into pterocarpans J. Chem. Soc., Perkin Trans.1 1986, 1, 1561-1563
88. North, J. T.; Kronenthal, D. R.; Pullockaran, A. J.; Real, S. D.; Chen, H. Y. Synthesis of 6-cyano-2,2-dimethyl-2 H -1-benzopyran and other substituted 2,2-dimethyl-2 H -1-benzopyrans J. Org. Chem. 1995, 60, 3397-3400
89. Kiss, L.; Kurtan, T.; Antus, S.; Benyei, A. Chiroptical properties and synthesis of enantiopure cis-and trans -pterocarpan skeleton Chirality 2003, 15, 558-563 (Pubitemid 36736621)
90. Slade, D.; Ferreira, D.; Marais, J. P. J. Circular dichroism, a powerful tool for the assessment of absolute configuration of flavonoids Phytochemistry 2005, 66, 2177-2215 (Pubitemid 41254096)
91. Sarver, J.; Klis, W.; Byers, J.; Erhardt, P. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123 and rhodamine 6G accumulation in multidrug resistant breast cancer cells J. Biomol. Screening 2002, 7, 29-34 (Pubitemid 34208860)
92. Trendel, J.; Ellis, N.; Sarver, J.; Klis, W.; Dhananjeyan, M.; Bykowski, C.; Reese, M.; Erhardt, P. Catalytically active peptidylglycine α-amidating monooxygenase in the media of androgen-independent prostate cancer cell lines J. Biomol. Screening 2008, 13, 804-809
93. Jansen, G. H.; Franke, H. R.; Wolbers, F.; Brinkhuis, M.; Vermes, I. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro Climacteric 2008, 11, 315-321 (Pubitemid 352032244)
94. Reed, C. A.; Berndtson, A. K.; Nephew, K. P. Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus Anticancer Drugs 2005, 16, 559-567 (Pubitemid 40685741)
95. Limer, J. L.; Parkes, A. T.; Speirs, V. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro Int. J. Cancer 2006, 119, 515-521 (Pubitemid 43955703)
96. Helferich, W. G.; Andrade, J. E.; Hoagland, M. S. Phytoestrogens and breast cancer: a complex story Inflammopharmacology 2008, 16, 219-226
97. Chang, E. C.; Charn, T. H.; Park, S. H.; Helferich, W. G.; Komm, B.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding Mol. Endocrinol. 2008, 22, 1032-1043 (Pubitemid 351629605)
98. Lavigne, J. A.; Takahashi, Y.; Chandramouli, G. V.; Liu, H.; Perkins, S. N.; Hursting, S. D.; Wang, T. T. Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study Breast Cancer Res. Treat. 2008, 110, 85-98 (Pubitemid 351793861)
99. Bondanelli, M.; Margutti, A.; Ambrosio, M. R.; Plaino, L.; Cobellis, L.; Petraglia, F.; degli Uberti, E. C. Blood growth hormone-binding protein levels in premenopausal and postmenopausal women: roles of body weight and estrogen levels J. Clin. Endocrinol. Metab. 2001, 86, 1973-1980 (Pubitemid 32472907)
100. Ottowitz, W. E.; Derro, D.; Dougherty, D. D.; Lindquist, M. A.; Fischman, A. J.; Hall, J. E. FDG-PET analysis of amygdalar-cortical network covariance during pre- versus post-menopausal estrogen levels: potential relevance to resting state networks, mood, and cognition Neuroendocrinol. Lett. 2008, 29, 467-474
101. Lau, K. M.; LaSpina, M.; Long, J.; Ho, S. M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation Cancer Res. 2000, 60, 3175-3182 (Pubitemid 30407914)
102. Maggiolini, M.; Recchia, A. G.; Carpino, A.; Vivacqua, A.; Fasanella, G.; Rago, V.; Pezzi, V.; Briand, P. A.; Picard, D.; Andò, S. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells J. Mol. Endocrinol. 2004, 32, 777-791 (Pubitemid 38885645)
103. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. C.; Brown, P. O.; Botstein, D.; Eystein Lønning, P.; Børresen-Dale, A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10869-10874 (Pubitemid 32878711)
104. Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; Brown, P. O.; Børresen-Dale, A. L.; Botstein, D. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 8418-8423 (Pubitemid 36842560)
105. Lupien, M.; Brown, M. Cistromics of hormone-dependent cancer Endocr.-Relat. Cancer 2009, 16, 381-389
106. Veldscholte, J.; Berrevoets, C. A.; Ris-Staplers, C.; Kuiper, G. G. M.; Jenster, G.; Trapman, J.; Brinkmann, A. O.; Mulder, E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J. Steroid Biochem. Mol. Biol. 1992, 41, 665-669
107. Klocker, H.; Culig, Z.; Hobisch, A.; Cato, A. C.; Bartsch, G. Androgen receptor alterations in prostatic carcinoma Prostate 1994, 25, 266-273 (Pubitemid 24364131)
108. Culig, Z.; Hobisch, A.; Hittmair, A.; Cronauer, M. V.; Radmayr, C.; Bartsch, G.; Klocker, H. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy Drugs Aging 1997, 10, 50-58 (Pubitemid 27057937)
109. Setchell, K. D.; Clerici, C.; Lephart, E. D.; Cole, S. J.; Heenan, C.; Castellani, D.; Wolfe, B. E.; Nechemias-Zimmer, L.; Brown, N. M.; Lund, T. D.; Handa, R. J.; Heubi, J. E. S -Equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora Am. J. Clin. Nutr. 2005, 81, 1072-1079 (Pubitemid 41724948)
110. Setchell, K. D.; Zhao, X.; Jha, P.; Heubi, J. E.; Brown, N. M. The pharmacokinetic behavior of the soy isoflavone metabolite S -(-)equol and its diastereoisomer R -(+)equol in healthy adults determined by using stable-isotope-labeled tracers Am. J. Clin. Nutr. 2009, 82, 1029-1037
111. Muthyala, R. S.; Ju, Y. H.; Sheng, S.; Williams, L. D.; Doerge, D. R.; Katzenellenbogen, B. S.; Helferich, W. G.; Katzenellenbogen, J. A. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R-and S -equols and their differing binding and biological activity through estrogen receptors alpha and beta Bioorg. Med. Chem. 2004, 12, 1559-1567 (Pubitemid 38304880)
112. Magee, P. J.; Raschke, M.; Steiner, C.; Duffin, J. G.; Pool-Zobel, B. L.; Jokela, T.; Wahala, K.; Rowland, I. R. Equol: a comparison of the effects of the racemic compound with that of the purified S -enantiomer on growth, invasion, and DNA integrity of breast and prostate cells in vitro Nutr. Cancer 2006, 54, 232-242 (Pubitemid 44316306)
113. Korach, K. S.; Levy, L. A.; Sarver, P. J. Estrogen receptor stereochemistry: receptor binding and hormonal responses J. Steroid Biochem. 1987, 27, 281-290 (Pubitemid 18059232)
114. Korach, K. S.; Chae, K.; Levy, L. A.; Duax, W. L.; Sarver, P. J. Diethylstilbestrol metabolites and analogs. Stereochemical probes for the estrogen receptor binding site J. Biol. Chem. 1989, 264, 5642-5647 (Pubitemid 19098024)
115. Korach, K. S.; Chae, K.; Gibson, M.; Curtis, S. Estrogen receptor stereochemistry: ligand binding and hormonal responsiveness Steroids 1991, 56, 263-270
116. Bocchinfuso, W. P.; Korach, K. S. Estrogen receptor residues required for stereospecific ligand recognition and activation Mol. Endocrinol. 1997, 11, 587-594 (Pubitemid 27193794)
117. Hoekstra, P. F.; Burnison, B. K.; Neheli, T.; Muir, D. C. Enantiomer-specific activity of o, p ′-DDT with the human estrogen receptor Toxicol. Lett. 2001, 125, 75-81 (Pubitemid 33043757)
118. Wallace, O. B.; Lauwers, K. S.; Dodge, J. A.; May, S. A.; Calvin, J. R.; Hinklin, R.; Bryant, H. U.; Shetler, P. K.; Adrian, M. D.; Geiser, A. G.; Sato, M.; Burris, T. P. A selective estrogen modulator for the treatment of hot flushes J. Med. Chem. 2006, 49, 843-846 (Pubitemid 43221631)
119. Weiser, M. J.; Wu, T. J.; Handa, R. J. Estrogen receptor-beta agonist diarylpropionitrile: biological activities of R-and S -enantiomers on behavior and hormonal response to stress Endocrinology 2009, 150, 1817-25
120. Franke, A.; Mueller, J.; Lietz, H.; Wiersdorff, W. W.; Hege, H. G.; Mueller, C. D.; Gries, J.; Lenke, D.; von Philipsborn, G.; Raschack, M. Aminopropanol derivatives of 2-hydroxy-β-phenylpropiophenones, pharmaceutical compositions and use. U.S. Patent US 4540697A, 1985; pp 1-10.
121. Romanelli, G.; Autino, J. C.; Baronetti, G.; Thomas, H. Efficient deprotection of phenol methoxymethyl ethers using a solid acid catalyst with Wells-Dawson structure Molecules 2001, 6, 1006-1011 (Pubitemid 38994459)
122. Fang, L.; Bykowski-Jurkiewicz, C.; Sarver, J. G.; Erhardt, P. W. Determination of esmolol and metabolite enantiomers within human plasma using chiral column chromatography J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2010, 878, 2449-2452
123. Smith, R. V.; Erhardt, P. W.; Rusterholz, D. B.; Barfknecht, C. F. NMR study of amphetamines using europium shift reagents J. Pharm. Sci. 1976, 65, 412-417
124. Tilley, W. D.; Wilson, C. M.; Marcelli, M.; McPhaul, M. J. Androgen receptor gene expression in human prostate carcinoma cell lines Cancer Res. 1990, 50, 5382-5386 (Pubitemid 20302992)
125. Levenson, A. S.; Jordon, V. C. MCF-7: the first hormone-responsive breast cancer cell line Cancer Res. 1997, 57, 3071-3078 (Pubitemid 27351713)
126. Mutoh, K.; Tsukahara, S.; Mitsuhashi, J.; Katayama, K.; Sugimoto, Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells Cancer Sci. 2006, 97, 1198-1204 (Pubitemid 44430645)
127. Wang, C. S.; Goulet, F.; Lavoie, J.; Drouin, R.; Auger, F.; Champetier, S.; Germain, L.; Tetu, B. Establishment and characterization of a new cell line derived from a human primary breast carcinoma Cancer Genet. Cytogenet. 2000, 120, 58-72 (Pubitemid 30410778)
128. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines J. Natl. Cancer Inst. 1990, 82, 1113-1118 (Pubitemid 20213251)
129. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenny, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug-screening J. Natl. Cancer Inst. 1990, 82, 1107-1112 (Pubitemid 20213250)
130. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 1991, 83, 757-766